Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

ClinicalTrials.gov ID: NCT03616834

Public ClinicalTrials.gov record NCT03616834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.

Study identification

NCT ID: NCT03616834
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Effector Therapeutics; Industry
Enrollment: 39 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

Tomivosertib (eFT-508) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 25, 2018 (Actual)
Primary completion: Jan 31, 2021 (Actual)
Completion: Jun 30, 2021 (Actual)
Last update posted: Mar 22, 2023

2018 – 2021

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of Arizona - Cancer Center	Tucson	Arizona	85724	—
Pacific Shores Medical Group	Long Beach	California	90813	—
Hoag Memorial Hospital Presbyterian	Los Angeles	California	90033	—
USC Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
St. Mary's Medical Center	San Francisco	California	94117	—
St. Joseph Heritage Healthcare	Santa Rosa	California	95403	—
Columbus Regional Research Institute	Columbus	Georgia	31904	—
Saint Alphonsus Regional Medical Center	Boise	Idaho	83706	—
Indiana University Health Melvin & Bren Simon Cancer Center	Indianapolis	Indiana	46202	—
Anne Arundel Medical Center	Annapolis	Maryland	21401	—
Karmanos Cancer Institute	Detroit	Michigan	48201	—
Gabrail Cancer Center	Canton	Ohio	44718	—
Universty of Toledo Medical Center	Toledo	Ohio	43614	—
Providence Portland Medical Center	Portland	Oregon	97213	—
Spartanburg Medical Center	Spartanburg	South Carolina	29303	—
Avera Cancer Institute	Sioux Falls	South Dakota	57105	—
Oncology Consultants	Houston	Texas	77024	—
Virginia Cancer Specialists, PC	Fairfax	Virginia	22031	—
University of Wisconsin Clinical Science Center	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03616834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 22, 2023 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03616834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →